{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:43:42Z","timestamp":1773366222192,"version":"3.50.1"},"reference-count":55,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["IF\/00409\/2014"],"award-info":[{"award-number":["IF\/00409\/2014"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["IF\/01179\/2013"],"award-info":[{"award-number":["IF\/01179\/2013"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["IF\/01302\/ 2013"],"award-info":[{"award-number":["IF\/01302\/ 2013"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["Lisboa-01-0145- FEDER-007317"],"award-info":[{"award-number":["Lisboa-01-0145- FEDER-007317"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["UID\/Multi\/04349\/2013"],"award-info":[{"award-number":["UID\/Multi\/04349\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["UID\/ BIO\/04565\/2013"],"award-info":[{"award-number":["UID\/ BIO\/04565\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["PTDC\/QUI-QUI\/118077\/2010"],"award-info":[{"award-number":["PTDC\/QUI-QUI\/118077\/2010"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["UID\/QUI\/00100\/ 2013"],"award-info":[{"award-number":["UID\/QUI\/00100\/ 2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["SFRH\/ BPD\/93513\/2013"],"award-info":[{"award-number":["SFRH\/ BPD\/93513\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia, FCT","doi-asserted-by":"publisher","award":["PD\/BD\/113475\/2015"],"award-info":[{"award-number":["PD\/BD\/113475\/2015"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2019,10,24]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Ruthenium complexes have been extensively investigated for their prospective value as alternatives to cisplatin. Recently, we reported the in vitro anticancer properties of a family of organometallic ruthenium( II)-cyclopentadienyl complexes and have explored their mechanism of action.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>The purpose of this study was to evaluate the in vivo antitumour efficacy and toxicity of one of these Ru(II) compounds, [RuCp(mTPPMSNa)(2,2\u2032-bipy)][CF3SO2] (TM85) which displayed an interesting spectrum of activity against several cancer cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Studies to assess the antitumour activity and toxicity were performed in a metastatic prostate (PC3) mice model using ICP-MS, nuclear microscopy, elemental analysis and Transmission Electron Microscopy (TEM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>TM85 showed low systemic toxicity but no significant tumour reduction, when administered at tolerated dose (20mg\/kg) over 10 days. Ru was mainly retained in the liver and less in kidneys, with low accumulation in tumour. Increased bilirubin levels, anomalous Ca and Fe concentrations in liver and mitochondria alterations were indicative of liver injury. The hepatotoxicity observed was less severe than that of cisplatin and no nephrotoxicity was found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Under the experimental conditions of this study, TM85 is less toxic than cisplatin, induces similar tumour reduction and avoids the formation of metastatic foci. No renal toxicity was observed by the analysis of creatinine levels and the effective renal plasma flow by 99mTc-MAG3 clearance. Hence, it can be considered a valuable compound for further studies in the field of Ru-based anticancer drugs.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871520619666190318152726","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T09:34:42Z","timestamp":1552988082000},"page":"1262-1275","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools"],"prefix":"10.2174","volume":"19","author":[{"given":"Lurdes","family":"Gano","sequence":"first","affiliation":[{"name":"Centro de Ciencias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, km 139.7, 2695-066 Bobadela LRS, Lisboa, Portugal"}]},{"given":"Teresa","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Departamento de Engenharia e Ciencias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, km 139.7, 2695-066 Bobadela LRS, Lisboa, Portugal"}]},{"given":"Ant\u00f3nio P.","family":"Matos","sequence":"additional","affiliation":[{"name":"Centro de Investigacao Interdisciplinar Egas Moniz, Campus Universitario, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal"}]},{"given":"Francisco","family":"Tortosa","sequence":"additional","affiliation":[{"name":"Instituto de Anatomia Patologica, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"given":"Tiago F.","family":"Jorge","sequence":"additional","affiliation":[{"name":"Centro de Quimica e Bioquimica, Faculdade de Ciencias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"given":"Maria S.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina Veterinaria, Universidade de Lisboa, Av. da Universidade Tecnica, Polo Universitario da Ajuda 1300-477 Lisboa, Portugal"}]},{"given":"Marta","family":"Martins","sequence":"additional","affiliation":[{"name":"Instituto de Medicina Molecular-Joao Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal"}]},{"given":"T\u00e2nia S.","family":"Morais","sequence":"additional","affiliation":[{"name":"Centro de Quimica Estrutural, Faculdade de Ciencias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"given":"Andreia","family":"Valente","sequence":"additional","affiliation":[{"name":"Centro de Quimica Estrutural, Faculdade de Ciencias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"given":"Ana I.","family":"Tomaz","sequence":"additional","affiliation":[{"name":"Centro de Qu\u00edmica Estrutural, Faculdade de Ci\u00eancias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"given":"Maria H.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Centro de Quimica Estrutural, Faculdade de Ciencias, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal"}]},{"given":"Fernanda","family":"Marques","sequence":"additional","affiliation":[{"name":"Centro de Ciencias e Tecnologias Nucleares, Instituto Superior T\u00e9cnico, Universidade de Lisboa, Estrada Nacional 10, km 139.7, 2695-066 Bobadela LRS, Lisboa, Portugal"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1158\/0008-5472.CAN-10-1253","volume":"70","author":"Milosavljevic N.","year":"2010","unstructured":"Milosavljevic N.; Duranton C.; Djerbi N.; Puech P.H.; Gounon P.; Lagadic-Gossmann D.; Dimanche-Boitrel M.T.; Rauch C.; Tauc M.; Counillon L.; Poet M.; Nongenomic effects of cisplatin: Acute inhibition of mechanosensitive transporters and channels without actin remodeling. Cancer Res 2010,70(19),7514-7522","journal-title":"Cancer Res"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"Florea A-M.","year":"2011","unstructured":"Florea A-M.; B\u00fcsselberg D.; Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011,3(1),1351-1371","journal-title":"Cancers"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"Dasari S.","year":"2014","unstructured":"Dasari S.; Tchounwou P.B.; Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014,740,364-378","journal-title":"Eur J Pharmacol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cbpa.2014.02.003","volume":"19","author":"Muhammad N.","year":"2014","unstructured":"Muhammad N.; Guo Z.; Metal-based anticancer chemotherapeutic agents. Curr Opin Chem Biol 2014,19,144-153","journal-title":"Curr Opin Chem Biol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2174\/092986706776360941","volume":"13","author":"Kostova I.","year":"2006","unstructured":"Kostova I.; Ruthenium complexes as anticancer agents. Curr Med Chem 2006,13(9),1085-1107","journal-title":"Curr Med Chem"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1039\/b904071d","volume":"1","author":"Levina A.","year":"2009","unstructured":"Levina A.; Mitra A.; Lay P.A.; Recent developments in ruthenium anticancer drugs. Metallomics 2009,1(6),458-470","journal-title":"Metallomics"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/1389557515666151001142012","volume":"16","author":"Abid M.","year":"2016","unstructured":"Abid M.; Shamsi F.; Azam A.; Ruthenium Complexes: An emerging ground to the development of metallopharmaceuticals for cancer therapy. Mini Rev Med Chem 2016,16(10),772-786","journal-title":"Mini Rev Med Chem"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cbdv.200890195","volume":"5","author":"Hartinger C.G.","year":"2008","unstructured":"Hartinger C.G.; Jakupec M.A.; Zorbas-Seifried S.; Groessl M.; Egger A.; Berger W.; Zorbas H.; Dyson P.J.; Keppler B.K.; KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers 2008,5(10),2140-2155","journal-title":"Chem Biodivers"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-010-1293-1","volume":"66","author":"Antonarakis E.S.","year":"2010","unstructured":"Antonarakis E.S.; Emadi A.; Ruthenium-based chemotherapeutics: Are they ready for prime time? Cancer Chemother Pharmacol 2010,66(1),1-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1039\/C4SC01255K","volume":"5","author":"Weiss A.","year":"2014","unstructured":"Weiss A.; Berndsen R.H.; Dubois M.; Muller C.; Schibli R.; Griffioen A.W.; Dyson P.J.; Nowak-Sliwinska P.; In vivo anti-tumor activity of the organometallic ruthenium(ii)-arene complex [Ru([small eta]6-p-cymene)Cl(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. Chem Sci 2014,5(12),4742-4748","journal-title":"Chem Sci"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.1039\/C5CS00134J","volume":"44","author":"Bergamo A.","year":"2015","unstructured":"Bergamo A.; Sava G.; Linking the future of anticancer metal-complexes to the therapy of tumour metastases. Chem Soc Rev 2015,44(24),8818-8835","journal-title":"Chem Soc Rev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/1568011053174873","volume":"5","author":"Zhao G.","year":"2005","unstructured":"Zhao G.; Lin H.; Metal complexes with aromatic N-containing ligands as potential agents in cancer treatment. Curr Med Chem Anticancer Agents 2005,5(2),137-147","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","volume":"54","author":"Gasser G.","year":"2011","unstructured":"Gasser G.; Ott I.; Metzler-Nolte N.; Organometallic anticancer compounds. J Med Chem 2011,54(1),3-25","journal-title":"J Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1039\/b508531b","volume":"38","author":"Yan Y.K.","year":"2005","unstructured":"Yan Y.K.; Melchart M.; Habtemariam A.; Sadler P.J.; Organometallic chemistry, biology and medicine: Ruthenium arene anticancer complexes. Chem Commun (Cambridge, England) 2005,38,4764-4776","journal-title":"Chem Commun (Cambridge, England)"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1021\/jm060596m","volume":"49","author":"Habtemariam A.","year":"2006","unstructured":"Habtemariam A.; Melchart M.; Fern\u00e1ndez R.; Parsons S.; Oswald I.D.H.; Parkin A.; Fabbiani F.P.A.; Davidson J.E.; Dawson A.; Aird R.E.; Jodrell D.I.; Sadler P.J.; Structure-activity relationships for cytotoxic Ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J Med Chem 2006,49(23),6858-6868","journal-title":"J Med Chem"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/2015\/859730","volume":"2015","author":"Motswainyana W.M.","year":"2015","unstructured":"Motswainyana W.M.; Ajibade P.A.; Anticancer activities of mononuclear Ruthenium(II) coordination complexes. Adv Chem 2015,2015,21","journal-title":"Adv Chem"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jinorgbio.2012.06.016","volume":"117","author":"Tomaz A.I.","year":"2012","unstructured":"Tomaz A.I.; Jakusch T.; Morais T.S.; Marques F.; de Almeida R.F.; Mendes F.; Enyedy E.A.; Santos I.; Pessoa J.C.; Kiss T.; Garcia M.H.; [RuII(eta(5)-C(5)H(5))(bipy)(PPh(3))](+), a promising large spectrum antitumour agent: cytotoxic activity and interaction with human serum albumin. J Inorg Biochem 2012,117,261-269","journal-title":"J Inorg Biochem"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1017\/S143192761300175X","volume":"19","author":"Corte-Real L.","year":"2013","unstructured":"Corte-Real L.; Matos A.P.; Alho I.; Morais T.S.; Tomaz A.I.; Garcia M.H.; Santos I.; Bicho M.P.; Marques F.; Cellular uptake mechanisms of an antitumour ruthenium compound: The endosomal\/lysosomal system as a target for anticancer metal-based drugs. Microsc Microanal 2013,19(5),1122-1130","journal-title":"Microsc Microanal"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinorgbio.2013.09.013","volume":"130","author":"Morais T.S.","year":"2014","unstructured":"Morais T.S.; Santos F.C.; Jorge T.F.; Corte-Real L.; Madeira P.J.; Marques F.; Robalo M.P.; Matos A.; Santos I.; Garcia M.H.; New water-soluble ruthenium(II) cytotoxic complex: Biological activity and cellular distribution. J Inorg Biochem 2014,130,1-14","journal-title":"J Inorg Biochem"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00775-014-1120-y","volume":"19","author":"Corte-Real L.","year":"2014","unstructured":"Corte-Real L.; Mendes F.; Coimbra J.; Morais T.S.; Tomaz A.I.; Valente A.; Garcia M.H.; Santos I.; Bicho M.; Marques F.; Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes. JBIC 2014,19(6),853-867","journal-title":"JBIC"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4155\/fmc.16.7","volume":"8","author":"Morais T.S.","year":"2016","unstructured":"Morais T.S.; Valente A.; Tomaz A.I.; Marques F.; Garcia M.H.; Tracking antitumour metallodrugs: Promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Future Med Chem 2016,8(5),527-544","journal-title":"Future Med Chem"},{"key":"ref=22","first-page":"902","volume":"891","author":"Chatterjee S.","year":"2012","unstructured":"Chatterjee S.; Roy A.; Laskar A.; Swarnakar S.; Electron microscopy in the perspective of modern biology: Ultravision and ultradimension. Curr Microsc Cont Adv Sci Technol (A M\u00e9ndez- Vilas, Ed) 2012,891,902","journal-title":"Curr Microsc Cont Adv Sci Technol (A M\u00e9ndez- Vilas, Ed)"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"S649","DOI":"10.1098\/rsif.2009.0166.focus","volume":"6","author":"Ortega R.","year":"2009","unstructured":"Ortega R.; Deves G.; Carmona A.; Bio-metals imaging and speciation in cells using proton and synchrotron radiation X-ray microspectroscopy. J R Soc Interface 2009,6(5),S649-S658","journal-title":"J R Soc Interface"},{"key":"ref=24","author":"Lopes J.","unstructured":"Lopes J.; Alves D.; Morais T.S.; Costa P.J.; Piedade M.F.;"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/acs.bioconjchem.6b00102","volume":"27","author":"Silva F.","year":"2016","unstructured":"Silva F.; Zambre A.; Campello M.P.; Gano L.; Santos I.; Ferraria A.M.; Ferreira M.J.; Singh A.; Upendran A.; Paulo A.; Kannan R.; Interrogating the role of receptor-mediated mechanisms: biological fate of peptide-functionalized radiolabeled gold nanoparticles in tumor mice. Bioconjug Chem 2016,27(4),1153-1164","journal-title":"Bioconjug Chem"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1530\/ERC-12-0285","volume":"20","author":"Wu X.","year":"2013","unstructured":"Wu X.; Gong S.; Roy-Burman P.; Lee P.; Culig Z.; Current mouse and cell models in prostate cancer research. Endocr Relat Cancer 2013,20(4),R155-R170","journal-title":"Endocr Relat Cancer"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1871520616666160922165133","volume":"17","author":"Mendes N.","year":"2017","unstructured":"Mendes N.; Tortosa F.; Valente A.; Marques F.; Matos A.; Morais T.S.; Tomaz A.I.; Gartner F.; Garcia M.H.; In vivo performance of a ruthenium-cyclopentadienyl compound in an orthotopic triple negative breast cancer model. Anticancer Agents Med Chem 2017,17(1),126-136","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.nimb.2007.02.014","volume":"260","author":"Pinheiro T.","year":"2007","unstructured":"Pinheiro T.; Pallon J.; Alves L.C.; Ver\u00edssimo A.; Filipe P.; Silva J.N.; Silva R.; The influence of corneocyte structure on the interpretation of permeation profiles of nanoparticles across skin. Nucl Instrum Methods Phys Res Secti B: Beam Interact Mater Atoms 2007,260(1),119-123","journal-title":"Nucl Instrum Methods Phys Res Secti B: Beam Interact Mater Atoms"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jemt.20402","volume":"70","author":"Verissimo A.","year":"2007","unstructured":"Verissimo A.; Alves L.C.; Filipe P.; Silva J.N.; Silva R.; Ynsa M.D.; Gontier E.; Moretto P.; Pallon J.; Pinheiro T.; Nuclear microscopy: A tool for imaging elemental distribution and percutaneous absorption in vivo. Microsc Res Tech 2007,70(4),302-309","journal-title":"Microsc Res Tech"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1017\/S1431927612001547","volume":"18","author":"Ynsa M.D.","year":"2012","unstructured":"Ynsa M.D.; Minquin R.; Rajendran R.; Pinheiro T.; Watt F.; Consequences of a fat diet in the distribution of minerals within pancreatic tissues of rats and rabbits. Microsc Microanal 2012,18(5),1060-1066","journal-title":"Microsc Microanal"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2340\/00015555-1601","volume":"94","author":"Pinheiro T.","year":"2014","unstructured":"Pinheiro T.; Silva R.; Fleming R.; Goncalves A.; Barreiros M.A.; Silva J.N.; Morliere P.; Santus R.; Filipe P.; Distribution and quantitation of skin iron in primary haemochromatosis: Correlation with total body iron stores in patients undergoing phlebotomy. Acta Derm Venereol 2014,94(1),14-19","journal-title":"Acta Derm Venereol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0168-583X(95)00901-9","volume":"109-110","author":"Grime G.W.","year":"1996","unstructured":"Grime G.W.; The \u201cQ factor\u201d method: Quantitative microPIXE analysis using RBS normalisation. Nucl Instrum Methods Phys Res Secti B: Beam Interact Mater Atoms 1996,109-110,170-174","journal-title":"Nucl Instrum Methods Phys Res Secti B: Beam Interact Mater Atoms"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/bioinformatics\/btm069","volume":"23","author":"Stacklies W.","year":"2007","unstructured":"Stacklies W.; Redestig H.; Scholz M.; Walther D.; Selbig J.; pcaMethods--a bioconductor package providing PCA methods for incomplete data. Bioinformatics (Oxford, England) 2007,23(9),1164-1167","journal-title":"Bioinformatics (Oxford, England)"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","volume":"1863","author":"Redza-Dutordoir M.","year":"2016","unstructured":"Redza-Dutordoir M.; Averill-Bates D.A.; Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta 2016,1863(12),2977-2992","journal-title":"Biochim Biophys Acta"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2174\/156800908783769391","volume":"8","author":"MacKenzie S.H.","year":"2008","unstructured":"MacKenzie S.H.; Clark A.C.; Targeting cell death in tumors by activating caspases. Curr Cancer Drug Targets 2008,8(2),98-109","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=36","first-page":"Unit 14.15","volume":"14","author":"Park S.I.","year":"2010","unstructured":"Park S.I.; Kim S.J.; McCauley L.K.; Gallick G.E.; Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protocols Pharmacol 2010,14,Unit 14.15","journal-title":"Curr Protocols Pharmacol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1039\/b811723c","volume":"43","author":"Fisher D.M.","year":"2008","unstructured":"Fisher D.M.; Fenton R.R.; Aldrich-Wright J.R.; In vivo studies of a platinum(ii) metallointercalator. Chem Commun 2008,43,5613-5615","journal-title":"Chem Commun"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1074\/jbc.273.24.14721","volume":"273","author":"Ivanov A.I.","year":"1998","unstructured":"Ivanov A.I.; Christodoulou J.; Parkinson J.A.; Barnham K.J.; Tucker A.; Woodrow J.; Sadler P.J.; Cisplatin binding sites on human albumin. J Biol Chem 1998,273(24),14721-14730","journal-title":"J Biol Chem"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1039\/C5CC01751C","volume":"51","author":"Ferraro G.","year":"2015","unstructured":"Ferraro G.; Massai L.; Messori L.; Merlino A.; Cisplatin binding to human serum albumin: A structural study. Chem Commun (Cambridge, England) 2015,51(46),9436-9439","journal-title":"Chem Commun (Cambridge, England)"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02987829","volume":"15","author":"Itoh K.","year":"2001","unstructured":"Itoh K.; 99mTc-MAG3: Review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann Nucl Med 2001,15(3),179-190","journal-title":"Ann Nucl Med"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0889-8588(05)70344-0","volume":"10","author":"Kim S.K.","year":"1996","unstructured":"Kim S.K.; Demetri G.D.; Chemotherapy and neutropenia. Hematol Oncol Clin 1996,10(2),377-395","journal-title":"Hematol Oncol Clin"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.smim.2016.02.003","volume":"28","author":"Hagerling C.","year":"2016","unstructured":"Hagerling C.; Werb Z.; Neutrophils: Critical components in experimental animal models of cancer. Semin Immunol 2016,28(2),197-204","journal-title":"Semin Immunol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","volume":"16","author":"Coffelt S.B.","year":"2016","unstructured":"Coffelt S.B.; Wellenstein M.D.; de Visser K.E.; Neutrophils in cancer: Neutral no more. Nat Rev Cancer 2016,16(7),431-446","journal-title":"Nat Rev Cancer"},{"key":"ref=44","volume":"5","author":"Muscella A.","year":"2014","unstructured":"Muscella A.; Vetrugno C.; Migoni D.; Biagioni F.; Fanizzi F.P.; Fornai F.; De Pascali S.A.; Marsigliante S.; Antitumour activity of [Pt(O,O\u2032-acac)(\u03b3-acac)(DMS)] in mouse xenograft model of breast cancer. Cell Death Dis 2014,5(1)","journal-title":"Cell Death Dis"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"Miller R.P.","year":"2010","unstructured":"Miller R.P.; Tadagavadi R.K.; Ramesh G.; Reeves W.B.; Mechanisms of cisplatin nephrotoxicity. Toxins 2010,2(11),2490-2518","journal-title":"Toxins"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"876","DOI":"10.5858\/arpa.2014-0214-RA","volume":"139","author":"Fisher K.","year":"2015","unstructured":"Fisher K.; Vuppalanchi R.; Saxena R.; Drug-induced liver injury. Arch Pathol Lab Med 2015,139(7),876-887","journal-title":"Arch Pathol Lab Med"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","volume":"1823","author":"Ganz T.","year":"2012","unstructured":"Ganz T.; Nemeth E.; Hepcidin and iron homeostasis. Biochim Biophys Acta 2012,1823(9),1434-1443","journal-title":"Biochim Biophys Acta"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/138920010791636149","volume":"11","author":"Wang Y.","year":"2010","unstructured":"Wang Y.; Juan L.V.; Ma X.; Wang D.; Ma H.; Chang Y.; Nie G.; Jia L.; Duan X.; Liang X.J.; Specific hemosiderin deposition in spleen induced by a low dose of cisplatin: Altered iron metabolism and its implication as an acute hemosiderin formation model. Curr Drug Metab 2010,11(6),507-515","journal-title":"Curr Drug Metab"},{"key":"ref=49","first-page":"409-414","volume":"06","author":"Liu N.","year":"1996","unstructured":"Liu N.; Deng Y.; Pan J.; Wu Y.; Zhou C.; Effects of cisplatin on element distribution in mouse kidney tissue assayed by multivariate statistical analysis. Int J PIXE 1996,06(01n02),409-414","journal-title":"Int J PIXE"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-60761-746-4_6","volume":"656","author":"Chandra S.","year":"2010","unstructured":"Chandra S.; Quantitative imaging of chemical composition in single cells by secondary ion mass spectrometry: Cisplatin affects calcium stores in renal epithelial cells. Methods Mol Biol (Clifton, NJ) 2010,656,113-130","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1039\/C4MT00238E","volume":"6","author":"Eljack N.D.","year":"2014","unstructured":"Eljack N.D.; Ma H.Y.; Drucker J.; Shen C.; Hambley T.W.; New E.J.; Friedrich T.; Clarke R.J.; Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallom: Integrated Biometal Sci 2014,6(11),2126-2133","journal-title":"Metallom: Integrated Biometal Sci"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.1039\/c2dt30217a","volume":"41","author":"Davis K.J.","year":"2012","unstructured":"Davis K.J.; Carrall J.A.; Lai B.; Aldrich-Wright J.R.; Ralph S.F.; Dillon C.T.; Does cytotoxicity of metallointercalators correlate with cellular uptake or DNA affinity? Dalton Trans 2012,41(31),9417-9426","journal-title":"Dalton Trans"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2014.11.006","volume":"8","author":"Mandal A.","year":"2015","unstructured":"Mandal A.; Viswanathan C.; Natural killer cells: In health and disease. Hematol Oncol Stem Cell Ther 2015,8(2),47-55","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1172\/JCI67867","volume":"123","author":"Zarjou A.","year":"2013","unstructured":"Zarjou A.; Bolisetty S.; Joseph R.; Traylor A.; Apostolov E.O.; Arosio P.; Balla J.; Verlander J.; Darshan D.; Kuhn L.C.; Agarwal A.; Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest 2013,123(10),4423-4434","journal-title":"J Clin Invest"},{"key":"ref=55","first-page":"55","volume":"12","author":"Oh G-S.","year":"2014","unstructured":"Oh G-S.; Kim H-J.; Shen A.; Lee S.B.; Khadka D.; Pandit A.; So H-S.; Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolytes Blood Press. E 2014,12(2),55-65","journal-title":"E"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T23:54:53Z","timestamp":1663113293000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170806\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,24]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520619666190318152726","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,24]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}